As mentioned earlier in this issue of TreatmentUpdate, the anti-cancer drug romidepsin (Istodax) can also inhibit the activity of HDAC (histone deacetylase), an enzyme that can help keep HIV infection latent.
Researchers with the pharmaceutical company Gilead Sciences performed laboratory experiments with cells extracted from 46 HIV-positive ART users whose CD4+ counts were above 350 cells and viral load less than 50 copies/ml. Specifically the researchers tested the following HDAC inhibitors:
Romidepsin appeared to be the most potent HDAC inhibitor in these test-tube studies. Its ability to bring HIV out of latency was consistent over time with cells from the same or different donors.
Regulatory authorities in the U.S. have approved the use of romidepsin, given intravenously at a dose of 15 mg per square metre of skin surface, for the treatment of certain cancers. However, according to the Gilead experiments, much lower doses can be used when attempting to bring HIV out of latency. These lower doses range between 2 and 5 mg/m2.
Based on these promising but preliminary experiments, expect a clinical trial of romidepsin in the future.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.